NCT02220894: A reported trial by Merck Sharp & Dohme LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02220894 |
|---|---|
| Title | A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Oct. 30, 2014 |
| Completion date | Sept. 4, 2018 |
| Required reporting date | Sept. 4, 2019, midnight |
| Actual reporting date | Feb. 14, 2019 |
| Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
| Days late | None |